Login
$RVMD
$166.04 -$0.83 (0.5%) After hours

$RVMD 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy

13 Oct 2026 8-K: Creation of a Direct Financial Obligation; Other Events

The information set forth under Item 8.01 below under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03.

01 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On August 27, 2026, Revolution Medicines, Inc. (the “Company”) agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of approximately 67...

26 Aug 2026 8-K: Other Events

On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are no...

05 Aug 2026 8-K: Results of Operations and Financial Condition

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

06 May 2026 8-K: Results of Operations and Financial Condition

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation

17 Apr 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

FIRST SUPPLEMENTAL INDENTURE, dated as of April 17, 2026, between Revolution Medicines, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base I...

16 Apr 2026 8-K: Other Events

Revolution Medicines, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives...

13 Apr 2026 8-K: Other Events

On April 13, 2026, Revolution Medicines, Inc. (the “Company”) shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenoc...

25 Feb 2026 8-K: Results of Operations and Financial Condition

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026

05 Nov 2025 8-K: Results of Operations and Financial Condition

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026

17 Oct 2025 8-K: Other Events

On October 16, 2025, Revolution Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted the Company a non-transferrable voucher for daraxonrasib, the Company’s RAS(ON) multi-selective inhibitor, u...

10 Sep 2025 8-K: Other Events

On September 10, 2025, Revolution Medicines, Inc. (the “Company”) provided the following pipeline updates.

06 Aug 2025 8-K: Results of Operations and Financial Condition

Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year

27 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2025, Revolution Medicines, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in m...

24 Jun 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

18 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

07 May 2025 8-K: Results of Operations and Financial Condition

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year

26 Feb 2025 8-K: Results of Operations and Financial Condition

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support